I
0.043
0.00 (-2.27%)
| Previous Close | 0.044 |
| Open | 0.042 |
| Volume | 20,226,376 |
| Avg. Volume (3M) | 17,151,637 |
| Market Cap | 325,384,448 |
| Price / Book | 2.35 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | 2,285.69% |
| Diluted EPS (TTM) | -0.020 |
| Quarterly Revenue Growth (YOY) | 67.60% |
| Total Debt/Equity (MRQ) | 1.08% |
| Current Ratio (MRQ) | 3.86 |
| Operating Cash Flow (TTM) | -101.73 M |
| Levered Free Cash Flow (TTM) | -69.35 M |
| Return on Assets (TTM) | -50.88% |
| Return on Equity (TTM) | -97.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | IMUGENE FPO [IMU] | - | - |
AIStockmoo Score
1.6
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 14.38% |
| % Held by Institutions | 6.65% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |